NCT02989636
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
StatusCompleted
PhasePhase 1
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 16 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 32 words Show 4 more changesShow less
- Trial completed
- Study completion date changed from estimate of Nov 2026 to Sep 2, 2026
- Study description revised
- Site details revised at 1 of 2 sites
- Minor Primary completion date changed from estimate of Nov 2024 to Apr 24, 2024
- Study completion date: Nov 2024 to Nov 2026
- Notable Primary and study completion dates: Nov 2023 to Nov 2024v20
- Minor Trial status: Enrolling by Invitation to Active, Not Recruiting
- Enrollment target: estimated 33 to confirmed 21
- Minor Trial status: Recruiting to Enrolling by Invitation
- Site details revised at 2 of 2 sites
Show 10 earlier versionsHide 10 earlier versions
- Notable Primary and study completion dates: Mar 2022 to Nov 2023v14
- Notable Eligibility criteria expanded, about 50 words
- Site contacts updated at 1 of 2 sites
- Notable Trial status: Active, Not Recruiting to Recruiting
- Eligibility criteria expanded, about 50 words
- Site details revised at 2 of 2 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates pushed to Mar 2022v9
- Minor Site contacts updated at 1 of 2 sites
- Collaborators: 1 to 3
- Minor Site details revised at 1 of 2 sitesv5
- Notable Eligibility criteria expanded, about 11 wordsv4
- Notable Eligibility criteria shortened, about 9 wordsv3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Start date: Jan 2017 to Mar 10, 2017
- Primary completion date: Jan 2020 to Mar 2020
- Study completion date: Mar 2021
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Timeframe: Up to 12 weeks after initial dose of nivolumab
Arms and interventions
Arm I (nivolumab)Experimental
Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Courses repeat every 14 days for 8 doses, then every 28 days for a total of 2 years in the absence of disease progression or unacceptable toxicity.
Arm II (nivolumab, SRS)Experimental
Patients receive nivolumab as in Arm I. Patients undergo stereotactic radiosurgery (SRS) as per standard of care on day 8 of course 1.
Other: Laboratory Biomarker Analysis
Biologicals: Nivolumab
Radiation: Stereotactic Radiosurgery
Sites
2 sites in 1 country